Precigen (PGEN) Other Non-Current Liabilities (2012 - 2026)
Precigen (PGEN) reported Other Non-Current Liabilities of $106000.0 for Q1 2026, down 99.87% year-over-year from $83.0 million in Q1 2025, and down 20.9% quarter-over-quarter from $134000.0 in Q4 2025.
Precigen (PGEN) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 13 years of Other Non-Current Liabilities data on file, last reported at $106000.0 in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $106000.0, down 99.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $106000.0 (down 99.87% YoY), and the FY2025 annual result was $134000.0, changed N/A from the prior year.
- Other Non-Current Liabilities eased to $106000.0 in Q1 2026 per PGEN's latest filing, from $134000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $83.0 million in Q1 2025 and troughed at $50000.0 in Q1 2022.
- A 3-year average of $27.0 million and a median of $148500.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities plunged 50.0% in 2022, then slumped 99.87% in 2026.
- A 3-year view of Other Non-Current Liabilities shows it stood at $50000.0 in 2022, then surged by 168.0% to $134000.0 in 2025, then slipped by 20.9% to $106000.0 in 2026.
- Business Quant data shows PGEN's Other Non-Current Liabilities at $106000.0 in Q1 2026, $134000.0 in Q4 2025, and $163000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Precigen | 1.32 Bn | 1.32 Bn | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Sep 30, 2025 | 163,000.00 |
| Jun 30, 2025 | 78.56 Mn |
| Mar 31, 2025 | 83.02 Mn |
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Sep 30, 2021 | 50,000.00 |
| Jun 30, 2021 | 50,000.00 |
| Mar 31, 2021 | 100,000.00 |
| Dec 31, 2020 | 100,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Jun 30, 2020 | 100,000.00 |
| Sep 30, 2019 | 221,000.00 |
| Jun 30, 2019 | 222,000.00 |
| Mar 31, 2019 | 662,000.00 |
| Dec 31, 2018 | 3.14 Mn |
| Sep 30, 2018 | 3.20 Mn |
| Jun 30, 2018 | 3.17 Mn |
| Mar 31, 2018 | 3.59 Mn |